共 56 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]
Schuette W(2004)Treatment of brain metastases from lung cancer: chemotherapy Lung Cancer 45 S253-S257
[3]
Hirsch FR(2017)Lung cancer: current therapies and new targeted treatments Lancet 389 299-311
[4]
Sezer A(2021)Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Lancet 397 592-604
[5]
Nishio M(2021)IMpower132: atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients Cancer Sci 112 1534-1544
[6]
Paz-Ares L(2020)A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407 J Thorac Oncol 15 1657-1669
[7]
Herbst RS(2020)Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC N Engl J Med 383 1328-1339
[8]
Jotte R(2020)Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial J Thorac Oncol 15 1351-1360
[9]
West H(2019)Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 20 924-937
[10]
Fehrenbacher L(2016)Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Lancet 387 1837-1846